| Literature DB >> 31338354 |
Yoshihide Mitani1, Etsuko Tsuda2, Hitoshi Kato3, Takashi Higaki4, Masako Fujiwara5, Shunichi Ogawa6, Fumiko Satoh7, Yoshikazu Nakamura8, Kei Takahashi9, Mamoru Ayusawa10, Tohru Kobayashi3, Fukiko Ichida11, Masaki Matsushima12, Masahiro Kamada13, Kenji Suda14, Hiroyuki Ohashi1, Hirofumi Sawada1, Takaaki Komatsu15, Kenji Waki16, Masanori Shinoda17, Ryusuke Tsunoda18, Hiroyoshi Yokoi19, Kenji Hamaoka20.
Abstract
Background: Acute coronary syndrome (ACS), which is emerging in adults long after confirmed (followed-up or lost-to-follow), or missed Kawasaki disease (KD), is poorly characterized. Methods andEntities:
Keywords: Kawasaki disease; acute coronary syndrome; coronary aneurysm; long-term issue; transition
Year: 2019 PMID: 31338354 PMCID: PMC6629790 DOI: 10.3389/fped.2019.00275
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.418
Clinical characteristics.
| 67 | 15 | 17 | 32 | 35 | |||
| Median age at ACS | 0.104 | <0.001 | |||||
| yo | 35 | 25 | 30 | 26.5 | 40 | ||
| (quartiles) | (26–47) | (21–30) | (24.5–38.5) | (23.5–33) | (36–57) | ||
| Male gender, | 51 (76) | 11 (73) | 16 (94) | 27 (84) | 0.106 | 24 (69) | 0.130 |
| Median age at acute illness, / | /14 | /16 | /30 | 0.208 | |||
| yo (quartiles) | 4 (1–8) | 3 (1–3.5) | 3 (1–5) | ||||
| Year 1965 and after, | 48 (72) | 15 (100) | 15 (88) | 30 (94) | 0.170 | 19 (54) | <0.001 |
| Calendar year at acute illness | /14 | /16 | /30 | 0.004 | |||
| Year 1980 and after, | 13 (93) | 7 (44) | 20 (67) | ||||
| Conventional risk factor, / | /64 | /14 | /16 | /30 | /34 | ||
| Smoking | 27 (42) | 3 (21) | 6 (38) | 9 (30) | 0.338 | 18 (53) | 0.064 |
| 0–1, | 48 (75) | 12 (86) | 14 (88) | 26 (87) | 0.886 | 22 (65) | 0.043 |
| 0 | 23 | 11 | 8 | 19 | 4 | ||
| 1 | 25 | 1 | 6 | 7 | 18 | ||
| 2 | 11 | 2 | 2 | 4 | 7 | ||
| 3 | 5 | 0 | 0 | 0 | 5 | ||
| STEMI/Cardiac arrest | 44 (66) | 11 (73) | 9 (53) | 20 (63) | 0.234 | 24 (69) | 0.601 |
| STEMI | 35 (52) | 8 | 7 | 15 | 20 | ||
| Cardiac arrest | 9 (13) | 3 | 2 | 5 | 4 | ||
| Unstable angina | 17 (25) | 3 | 6 | 9 | 8 | ||
| Non-STEMI | 6 (9) | 1 | 2 | 3 | 3 | ||
| Chest pain, | 57 (85) | 11 (73) | 14 (82) | 25 (78) | 0.538 | 32 (91) | 0.127 |
| Shock, | 13 | 2 | 3 | 5 | 8 | ||
| Physical status at ACS, / | /63 | /13 | /15 | /28 | /35 | ||
| Exercise-related, | 15 (24) | 5 (38) | 3 (20) | 8 (29) | 0.281 | 7(20) | 0.427 |
| At rest | 38 | 6 | 10 | 16 | 22 | ||
| During sleeping | 10 | 2 | 2 | 4 | 6 | ||
| Medication (+), | 15 (22) | 13 (87) | 0 (0) | 13(41) | <0.001 | 2 (6) | 0.001 |
| Antiplatelet | 15 | 13 | 0 | 13 | 2 | ||
| Warfarin | 3 (4) | 3 (20) | 0 (0) | 3 (9) | 0 (0) | ||
| β blocker | 8 | 6 | 0 | 6 | 2 | ||
| Nitrate | 2 | 2 | 0 | 2 | 0 | ||
| ACEI/ARB | 3 | 1 | 0 | 1 | 2 | ||
| Statin | 0 | 0 | 0 | 0 | 0 | ||
| PCI before ACS, | 4 (6) | 3 (20) | 0 (0) | 3 (9) | 0.053 | 1 (3) | 0.261 |
| CABG before ACS, | 2 (3) | 0 (0) | 1 (6) | 1 (3) | 0.340 | 1 (3) | 0.949 |
| History of AMI, | 4 (6) | 1 (7) | 1 (6) | 2 (6) | 0.927 | 2 (6) | 0.926 |
| Medication 1m after ACS, / | /52 | /10 | /14 | /24 | /28 | ||
| Medication (+), | 51 (98) | 10 (100) | 13 (93) | 23 (96) | 0.388 | 28 (100) | 0.275 |
| Antiplatelet | 51 | 10 | 13 | 23 | 28 | ||
| Warfarin | 29 (56) | 7 (70) | 6 (43) | 13 (54) | 16 (57) | ||
| β blocker | 18 | 4 | 1 | 15 | 13 | ||
| Nitrate | 8 | 2 | 3 | 5 | 3 | ||
| ACEI/ARB | 23 | 3 | 3 | 6 | 17 | ||
| Statin | 18 | 0 | 6 | 6 | 12 | ||
| Death at one month, | 13 (19) | 4 (27) | 3 (18) | 7 (22) | 0.538 | 6 (17) | 0.625 |
KD, denotes Kawasaki disease; ACS, acute coronary syndrome; STEMI, ST elevation myocardial infarction; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting; AMI, acute myocardial infarction. Traditional coronary factors included dyslipidemia, hypertension, smoking, diabetes, and family history of AMI. If missing data was included in any item, the number of available data was specified as /N. Percentages, median values and quartile ranges were calculated on the basis of the available data in each item.
Figure 1Age at ACS and calendar year of birthdate and KD diagnosis, by the type of KD diagnosis and the follow-up status. (A) Age at acute coronary syndrome, (B) Calendar year of birthdate, (C) Calendar year of KD diagnosis. ACS denotes acute coronary syndrome; KD, Kawasaki disease; CAL, coronary artery lesion; CAG, coronary angiography; UCG, ultrasound cardiography; n, number of patients. Number in parenthesis indicates reference number.
Characteristics of the culprit lesions.
| Number of patients | 67 | 15 | 17 | 32 | 35 | ||
| Culprit lesion, / | /64 | /13 | /16 | /29 | /35 | ||
| RCA, | 32 (50) | 6 (46) | 8 (50) | 14 (48) | 18 (51) | ||
| LCA, | 35 (55) | 7 (55) | 8 (50) | 15 (52) | 0.837 | 20 (57) | 0.665 |
| LMT, | 6 | 1 | 1 | 3 | |||
| LAD, | 28 | 7 | 6 | 15 | |||
| LCX, | 8 | 2 | 2 | 5 | |||
| Demonstrable thrombosis, / | /57 | /9 | /16 | /25 | 0.282 | /32 | 0.142 |
| | 42(74) | 7(78) | 9 (56) | 16 (64) | 26(81) | ||
| Size of AN in the vicinity, / | /61 | /13 | /17 | /30 | /31 | ||
| 3.0–3.9 mm | 11 | 1 | 4 | 5 | 6 | ||
| 4.0–5.9 mm | 11 | 1 | 3 | 4 | 7 | ||
| 6.0–7.9 mm | 16 | 2 | 5 | 7 | 9 | ||
| ≥8.0 mm | 23 (38) | 9 (69) | 5 (29) | 14 (47) | 0.030 | 9 (29) | 0.155 |
| IVUS-derived calcification, / | /13 | /3 | /4 | /7 | 0.350 | /6 | 0.335 |
| | 12 (92) | 3 (100) | 3 (75) | 6 (86) | 6 (100) | ||
| Emergency treatment, / | /64 | /13 | /17 | /30 | /34 | ||
| Thrombolysis/Aspiration | 29 (45) | 6 (46) | 4 (24) | 10 (33) | 0.193 | 19 (56) | 0.071 |
| IC thrombolysis | 13 | 4 | 3 | 6 | |||
| Thrombus aspiration | 23 | 4 | 2 | 17 | |||
| POBA | 22 | 4 | 5 | 13 | |||
| Stenting | 18 | 3 | 2 | 13 | |||
| CABG | 10 | 2 | 2 | 6 | |||
RCA, denotes right coronary artery; LCA, left coronary artery; LMT, left main coronary trunk; LAD, left anterior descending coronary artery; LCX, left circumflex coronary artery; AN, aneurysm; IVUS, intravascular ultrasound; IC, intracoronary; POBA, plain old balloon angioplasty; CABG, coronary artery bypass grafting.
Treatment for acute KD and culprit lesions early and ≥5 years after acute KD.
| Treatment for acute KD, / | /18 |
| No specific treatment, | 3 (17) |
| Anti-platelet agent, | 14 (78) |
| Intravenous immunoglobulin, | 5 (28) |
| Steroid, | 4 (22) |
| Prospective culprit lesion, / | /14 |
| 3.0–3.9 mm, | 0 (0) |
| 4.0–5.9 mm, | 0 (0) |
| 6.0–7.9 mm, | 5 (36) |
| ≥8.0 mm, | 9 (64) |
| Patients with multi-vessel CAL, /N | /14 |
| 10 (71) | |
| (median, interquartile range) | 16 y (13–18 y) |
| The prospective culprit lesion, / | /18 |
| ≥8 mm AN/stenosis (>75%), | 4 (22) |
| ≥8 mm AN/stenosis (≤75%), | 5 (28) |
| <8 mm AN/stenosis (>75%), | 3 (17) |
| <8 mm AN/stenosis (≤75%), | 6 (33) |
CAL denotes coronary artery lesion.Number of available patients in each subgroup in ‘Treatment for acute KD': followed-up patients, n = 11; lost-to-follow patients, n = 7. ‘CAL during or in the convalescence of acute KD': followed-up patients, n = 10; lost-to-follow patients, n = 4. ‘CAL ≥5 years after KD': followed-up patients, n = 12; lost-to-follow patients, n = 6.